Symptomatic and preventive effects of the novel phosphodiesterase-9 inhibitor BI 409306 in an immune-mediated model of neurodevelopmental disorders

BI 409306, a phosphodiesterase-9 inhibitor under development for treatment of schizophrenia and attenuated psychosis syndrome (APS), promotes synaptic plasticity and cognition. Here, we explored the effects of BI 409306 treatment in the polyriboinosinic-polyribocytidilic acid (poly[I:C])-based mouse...

Descripción completa

Detalles Bibliográficos
Autores principales: Scarborough, Joseph, Mattei, Daniele, Dorner-Ciossek, Cornelia, Sand, Michael, Arban, Roberto, Rosenbrock, Holger, Richetto, Juliet, Meyer, Urs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209175/
https://www.ncbi.nlm.nih.gov/pubmed/33941860
http://dx.doi.org/10.1038/s41386-021-01016-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209175/
https://www.ncbi.nlm.nih.gov/pubmed/33941860
http://dx.doi.org/10.1038/s41386-021-01016-3

Ejemplares similares